Serological evidence of Flavivirus circulation in human populations in Northern Kenya: an assessment of disease risk 2016–2017

E. Chepkorir1,2*, D. P. Tchouassi1, S. L. Konongoi3, J. Lutomiah3, C. Tigoi1, Z. Irura4, F. Eyase5, M. Venter2 and R. Sang1

**Abstract**

**Background:** Yellow fever, Dengue, West Nile and Zika viruses are re-emerging mosquito-borne Flaviviruses of public health concern. However, the extent of human exposure to these viruses and associated disease burden in Kenya and Africa at large remains unknown. We assessed the seroprevalence of Yellow fever and other Flaviviruses in human populations in West Pokot and Turkana Counties of Kenya. These areas border Uganda, South Sudan and Ethiopia where recent outbreaks of Yellow fever and Dengue have been reported, with possibility of spillover to Kenya.

**Methodology:** Human serum samples collected through a cross-sectional survey in West Pokot and Turkana Counties were screened for neutralizing antibodies to Yellow fever, Dengue-2, West Nile and Zika virus using the Plaque Reduction Neutralization Test (PRNT). Seroprevalence was compared by county, site and important human demographic characteristics. Adjusted odds ratios (aOR) were estimated using Firth logistic regression model.

**Results:** Of 877 samples tested, 127 neutralized with at least one of the four flaviviruses (14.5, 95% CI 12.3–17.0%), with a higher proportion in Turkana (21.1%, n = 87/413) than in West Pokot (8.6%, n = 40/464). Zika virus seroprevalence was significantly higher in West Pokot (7.11%) than in Turkana County (0.24%; χ² P < 0.0001). A significantly higher Yellow fever virus seroprevalence was also observed in Turkana (10.7%) compared to West Pokot (1.29%; χ² P < 0.0001). A high prevalence of West Nile virus was detected in Turkana County only (10.2%) while Dengue was only detected in one sample, from West Pokot. The odds of infection with West Nile virus was significantly higher in males than in females (aOR = 2.55, 95% CI 1.22–5.34). Similarly, the risk of Zika virus infection in West Pokot was twice higher in males than females (aOR = 2.01, 95% CI 0.91–4.41).

**Conclusion:** Evidence of neutralizing antibodies to West Nile and Zika viruses indicates that they have been circulating undetected in human populations in these areas. While the observed Yellow Fever prevalence in Turkana and West Pokot Counties may imply virus activity, we speculate that this could also be as a result of vaccination following the Yellow Fever outbreak in the Omo river valley, South Sudan and Uganda across the border.

**Keywords:** Dengue virus, Yellow fever virus, West Nile virus, Zika virus, Seroprevalence, Plaque reduction neutralization test, Flaviviruses risk assessment, Northern Kenya

* Correspondence: echepkorir@icipe.org
1 International Centre of Insect Physiology and Ecology, P. O. Box 30772-00100, Nairobi, Kenya
2 Center for Viral Zoonoses, Department of Medical Virology, University of Pretoria, P. O. Box 323, Arcadia 0007, South Africa
Full list of author information is available at the end of the article
Background

Yellow fever virus (YFV), Dengue virus (DENV), West Nile virus (WNV) and Zika virus (ZIKV) are important mosquito-borne Flaviviruses that have a potential to cause severe disease and mortalities in humans with economic and ecological consequence [1, 2]. Approximately 831 million people in Africa are at risk of infection with at least one of these viruses [3]. Epidemiologic studies on these mosquito-borne viruses remain a priority given their risk of global spread and high epidemic potential.

There have been no cases of Yellow Fever (YF) in Kenya since the first and last ever documented outbreak in 1992–95 [4, 5]. However, recent re-emergence of the virus with major outbreaks in border countries of Uganda, Ethiopia and South Sudan [6–9] and regionally in Angola and Democratic Republic of Congo has become a major public health concern [10]. Dengue is currently endemic in parts of Kenya, with outbreaks reported in some specific geographic zones in the coast and northern frontier of Kenya associated with dengue Serotypes 1–3, and neighboring countries like South Sudan, Somalia and Tanzania [11, 12]. West Nile on the other hand, was first isolated in Uganda in 1937 and is now one of the re-emerging zoonotic mosquito-borne pathogens whose occurrence and geographical range continues to spread [2].

Zika virus was first discovered in Uganda in 1947 [13], and since then, there has been limited data available on its circulation in the region. Previously, virological and immunological evidence suggested that although ZIKV was distributed widely in Africa and Asia, Zika fever was not a disease of substantial concern to human beings because only 14 cases had been documented worldwide [14, 15]. In 2016 outbreaks of the virus were reported in the Americas [16] that led to the World Health Organization (WHO) declaration of Zika virus as a public health emergency of international concern. The increased detection of Zika virus worldwide and its association with increasingly large outbreaks of disease has heightened awareness of this emerging mosquito-transmitted pathogen [17].

There is limited epidemiologic knowledge about the presence and spread of arboviral diseases in northern Kenya. Surveillance capacities are lacking, with most resources for study and control of these viruses being focused on epidemic periods. As such, the magnitude of human exposure and the burden of these important Flavivirus diseases in this region remain poorly understood. West Pokot and Turkana Counties are located in areas that border countries that have had and reported outbreaks of these Flaviviruses in recent times and therefore the risk of virus spread from neighboring countries remains high. This study sought to determine the seroprevalence of Yellow fever, Dengue, West Nile and Zika viruses among the human populations in the border locations of West Pokot County bordering Uganda and Turkana County bordering South Sudan and Ethiopia to the north.

Materials and methods

Ethical approval

This study was approved by Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit (SERU) (under protocol number KEMRI-SERU 2787) and University of Pretoria. All adult participants provided written informed consent and assent for child/minor participants. Only those who consented or assented were included in the study.

Study sites and study population

This was a cross sectional population based study conducted in Turkana and West Pokot Counties of Kenya. Six sites each were selected and sampled in West Pokot County: Kacheliba sub-county (Kokipei, Sangakai, Kanyerus, Shaba, Longarkau and Pkotong) and Turkana County, Lokitoung sub-county (Elelea, Prigan, Kare-Edome, Nayanaesanyati, Old gunner and Lowarengak) (Fig. 1). Turkana County borders three high risk countries for YF, based on past and recent outbreaks. These include Ethiopia to the North, along the Omo River Valley, which experienced one of the largest YF outbreaks in East Africa in 1968 [18] and recently in 2013 [9]. Also, to the North is South Sudan and Uganda to the west. West Pokot borders Uganda which experienced an outbreak of YF in 2011 and 2016 [7, 8]. All the three neighboring countries have experienced YF outbreaks in locations that are close to Turkana and Kacheliba (West Pokot; Fig. 1).

The human populations in West Pokot are mainly nomadic pastoralists although there is increasing tendency for them to move to market centers and become sedentary. In Turkana, they are mainly nomadic pastoralists and tend to look for pasture in areas surrounding the lake, and some engage in fishing. As of 2009, the population of Turkana was 855,399 and West Pokot 512,690 [19]. The livelihoods of these communities are characterized by lack of most basic amenities like water, health care, education and even food. Corollary, they sometimes migrate as far as the neighboring countries of Uganda, South Sudan and Ethiopia in search of water and pasture, a practice that may put them at risk of exposure to YF and other exotic viruses.

Sample collection

Human blood samples were collected through a cross-sectional study designed into village clusters based on administrative boundaries, in West Pokot and Turkana Counties, Kenya (Fig. 1) in February 2016 and August...
Blood samples were collected from a randomized asymptomatic human population within the village clusters. Both males and females aged between 12 and 95, who consented/assented to participate in the study, were included. An individual was excluded if he/she declined to give assent/consent. Gender, age, place of residence, occupation, YF vaccination and travel history were recorded for each study participant. A total volume of 5 ml of blood was collected from each study participant using vacutainer tubes with a clot activator. The tubes with blood samples were left to stand at room temperature for 10 min and then placed on sample carrier at 2–8 °C for transport to the field laboratory. At the field laboratory, the serum was processed by centrifugation at a relative centrifugal force (RCF) of 112 for 3 min, then aliquoted into 1 ml volumes, placed in two sterile cryovials. All the serum samples collected were preserved in liquid nitrogen and transported to the Emerging infectious Disease (EID) laboratory at the International Centre of Insect Physiology and Ecology (icipe) Duduville Campus in Nairobi, where they were stored at −80 °C until tested.

Plaque reduction neutralization assay (PRNT)
Samples were retrieved from the freezer, aliquoted in volumes of 30 μl, heat inactivated at 56 °C for 30 min and then tested for neutralizing antibodies to YF (YFXSMB), Dengue-2 (008/01/2012), West Nile (AMH005348) and Zika (MR766) viruses in two-fold serum dilutions from 1:10 to 1:320 using PRNT 90. Respective virus isolates were diluted to a standard concentration that gave 20–50 plaques. Appropriate 10-fold dilutions of serum samples were prepared in maintenance media (Minimum Essential Media Eagles, Sigma with Earle's salts and reduced NaHCO₃) supplemented with 2% heat-inactivated fetal bovine serum (FBS), 2% L-glutamine, 2% penicillin/amphotericin B (Sigma-Aldrich, St. Louis, MO), starting with a seropositivity threshold of 1:10. The serum dilutions were added to microcentrifuge tubes containing the standard concentration of the diluted virus and incubated for 1 h at 37 °C. The virus–antibody mixture was inoculated on a 24-well plate containing confluent Vero cell monolayer (VERO E6) and incubated for 1 h for virus adsorption. After adsorption process, an overlay...
of methylcellulose (2.5%) (Sigma) mixed with 2X Minimum Essential Medium (Sigma), was added into the wells. Between 6 and 14 days depending on the virus tested, the plaques were fixed using 10% formalin (Sigma), stained with 0.25% crystal violet (Sigma) diluted in absolute ethanol and the plaques counted manually as described previously [20, 21]. Endpoint titres were determined as the reciprocal of the highest serum dilution giving ≥90% reduction in plaque counts [22].

Statistical analysis
Field data captured were stored in a password-protected database linked to the laboratory results, and were analyzed using R version 3.3.1 [23]. First, we characterized the study participants with respect to exposure to the Flaviviruses tested. Reported prevalence was compared by county, site and important demographic characteristics such as sex, age, occupation and YF vaccination status. Comparisons of proportions and evaluation of heterogeneity of the seropositive proportions across the independent variables listed above were performed using Chi Square test. The 95% confidence intervals (CIs) for the proportions positive for a virus were estimated using the Agresti-Coull method [24]. Next, we fitted for each of the three most prevalent Flaviviruses with a frequency of six or more positive samples (i.e., YFV in both West Pokot and Turkana; ZIKV in West Pokot; WNV in Turkana), a multiple logistic regression model with covariates as site, sex, age in years, occupation, whether the participant was a herdsman, and whether the participant reported to have or have not received YF vaccination. As the data were sparse, Firth’s logistic regression [25] was chosen. Firth’s approach reduces the bias in maximum likelihood (ML) estimates of coefficients when binary events are rare by penalizing the likelihood function using Jeffreys invariant prior. In addition, it also allows for the computation of reliable, finite estimates of coefficients in the case of separation, where ML estimation fails [26]. All tests were performed at 5% significance level.

Results

Demographic profile of study participants
Table 1 shows the distribution of the study participants with respect to their demographic characteristics for the individual and combined counties. A total of 877 serum samples were collected; 464 from West Pokot and 413 from Turkana. Of these samples, 64% (565/877) were from females and 36% (312/877) males. In both counties, there were more female participants than males. The sampled participants’ age ranged from 13 to 92 years, and their mean (median) age was 39 years (35 years). About three in five study participants were farmers, but this varied across the counties as almost all the participants (98.5%) in West Pokot were farmers. About 23% of the study participants were housewives or female domestic servants, 9% fishermen, 2.4% were either teachers or students, and the rest were involved in other economic activities. Most participants (42%) indicated they had not been vaccinated against YF, 36% did not know their YF vaccination status, and 22% indicated that they had been vaccinated.

Prevalence of Flaviviruses in west Pokot and Turkana counties
Of 877 samples tested, 127 (14.5, 95% CI 12.3–17.0%) were positive for at least one of the four Flaviviruses. This proportion was, however, higher in Turkana (21.1%) than in West Pokot (8.6%; P < 0.0001). Figure 2 presents plaque reduction neutralization test results stratified by county. First, the figure shows that in general, the virus to which the most neutralizing antibodies were present was YFV, followed by WNV, ZIKV and DENV. Second, there was variability in the prevalence of

| Table 1 Demographic characteristics of study participants from Kacheliba in West Pokot and Lokitoung in Turkana Counties |
|-----------------|-----------------|-----------------|-----------------|
| Characteristic   | West Pokot County | Turkana County | Combined        |
| N    | %    | N    | %    | N    | %    |
|-------|------|------|------|------|------|
| All   | 464  | 100.0 | 413  | 100.0 | 877  | 100.0 |
| Sex   |      |       |      |       |      |       |
| Female| 324  | 69.8  | 241  | 58.4  | 565  | 64.4  |
| Male  | 140  | 30.2  | 172  | 41.6  | 312  | 35.6  |
| Age (years) |      |       |      |       |      |       |
| 13–19 | 14   | 3.1   | 48   | 11.6  | 62   | 7.1   |
| 20–29 | 101  | 21.8  | 139  | 33.7  | 240  | 27.4  |
| 30–39 | 106  | 22.8  | 86   | 20.8  | 192  | 21.9  |
| 40–49 | 77   | 16.6  | 38   | 9.2   | 115  | 13.1  |
| 50+   | 166  | 35.8  | 102  | 24.7  | 268  | 30.6  |
| Occupation |      |       |      |       |      |       |
| Farmer | 457  | 98.5  | 71   | 17.2  | 528  | 60.2  |
| Wife/housegirl | 0     | 0.0   | 198  | 47.9  | 198  | 22.6  |
| Fisherman/vendor | 0     | 0.0   | 82   | 19.9  | 82   | 9.4   |
| Teacher/student | 4     | 0.9   | 17   | 4.1   | 21   | 2.4   |
| Other  | 3    | 0.7   | 45   | 10.9  | 48   | 5.5   |
| Herdsman |      |       |      |       |      |       |
| No    | 425  | 91.6  | 373  | 90.3  | 798  | 91.0  |
| Yes   | 39   | 8.4   | 40   | 9.7   | 79   | 9.0   |
| Yellow Fever vaccinated |      |       |      |       |      |       |
| No    | 192  | 41.4  | 176  | 42.6  | 368  | 42.0  |
| Yes   | 182  | 39.2  | 11   | 2.7   | 193  | 22.0  |
| don’t know | 90    | 19.4  | 226  | 54.7  | 316  | 36.0  |
the *Flaviviruses* between the two counties. Whereas DENV neutralizing antibodies were detected in one sample (0.22% prevalence) from West Pokot only, WNV antibodies were detected in Turkana only (42/413, prevalence = 10.2%). While YFV and ZIKV antibodies were detected in samples from both counties, YFV was significantly more prevalent in Turkana (10.7%) than West Pokot (1.29%; $\chi^2 P < 0.0001$). The converse was true for ZIKV.

Table 2 summarizes PRNT results across six sites within each county. There was variability in *Flavivirus* prevalence across the sites within as well as between the counties. Yellow fever prevalence ranged from 0% in Kokipei, Shaba, Longarkau, and Pkotong to about 4% in Kanyerus in West Pokot. In Turkana, YF prevalence varied from about 7% in Kare Edome to about 20% in Elelea. For West Nile virus antibodies, which were detected in Turkana only, the prevalence varied from 8% in Prigan to 11.1% in Elelea. Also samples from only two sites had neutralizing antibodies to three viruses detected. These were Sangakai in West Pokot (DEN, YF, and ZIK) and Elelea in Turkana (YF, ZIK, and WN).

Prevalence of the three most prevalent *Flaviviruses* (ZIKV, YFV and WNV) varied by age group in both counties (Fig. 3). In West Pokot, the prevalence of ZIKV was highest among those in the age group 13–19 years and lowest among the age group 20–29 years, though the difference was not significant. Yellow fever neutralizing antibodies were more among the age group 30–39 years and less among those aged 50+ years, though the

**Table 2** *Flavivirus* PRNT90 endpoint titre results for sites in Kacheliba, West Pokot County and Lokitoung, Turkana County

| Site          | Number of samples tested | Number of samples (%) positive of each Flavivirus |  |  |
|---------------|--------------------------|--------------------------------------------------|--|--|
| West Pokot    |                          |                                                  |  |  |
| Kokipei       | 100                      | 0 (0.00)                                         | 0 (0.00) | 8 (8.00) | 0 (0.00) |
| Sangakai      | 66                       | 1 (1.52)                                         | 2 (3.03) | 6 (9.09) | 0 (0.00) |
| Kanyerus      | 113                      | 0 (0.00)                                         | 4 (3.54) | 13 (11.50) | 0 (0.00) |
| Shaba         | 73                       | 0 (0.00)                                         | 0 (0.00) | 3 (4.11) | 0 (0.00) |
| Longarkau     | 60                       | 0 (0.00)                                         | 0 (0.00) | 1 (1.67) | 0 (0.00) |
| Pkotong       | 52                       | 0 (0.00)                                         | 0 (0.00) | 2 (3.85) | 0 (0.00) |
| Total         | 464                      | 1 (0.22)                                         | 6 (1.29) | 33 (7.11) | 0 (0.00) |
| Turkana       |                          |                                                  |  |  |
| Elelea        | 63                       | 0 (0.00)                                         | 12 (19.05) | 1 (1.59) | 7 (11.11) |
| Prigan        | 25                       | 0 (0.00)                                         | 2 (8.00) | 0 (0.00) | 2 (8.00) |
| Kare Edome    | 61                       | 0 (0.00)                                         | 4 (6.56) | 0 (0.00) | 6 (9.84) |
| Nayanaesanyati| 69                       | 0 (0.00)                                         | 6 (8.70) | 0 (0.00) | 7 (10.14) |
| Old gunner    | 56                       | 0 (0.00)                                         | 5 (8.93) | 0 (0.00) | 5 (8.93) |
| Lowarengak    | 139                      | 0 (0.00)                                         | 15 (10.79) | 0 (0.00) | 15 (10.79) |
| Total         | 413                      | 0 (0.00)                                         | 44 (10.65) | 1 (0.24) | 42 (10.17) |
difference was not significant. In Turkana County, the prevalence of WNV was highest among those aged ≥50 years ($\chi^2 P = 0.048$) and lowest among the age group 20–29 years. Zika virus antibodies were only detected in the 50+ years age group in Turkana County. In general, variation between seroprevalence to *Flaviviruses* was quite limited between age groups.

*Flaviviruses* that had more than 30 samples neutralizing with either of the three most prevalent viruses for each county (i.e., West Pokot: ZIKV ($n = 33$); Turkana: YFV ($n = 44$), WNV ($n = 42$) by demographic characteristics are presented in Additional file 1: Table S1.

Firth’s logistic regression model results

Table 3 shows the adjusted odds ratios (aORs) and the associated 95% confidence intervals estimated using Firth’s logistic regression model. The data show that in Turkana County, males were about three times more likely to be infected with WNV than females (aOR = 2.55, 95% CI 1.22–5.34). There was a two-fold likelihood of WNV infection among the age group 50+ years compared to the age group 13–19 years. There was no difference in YF seroprevalence in Turkana by site, sex, age group and vaccination status. In West Pokot County, YF infection was eight times higher among study participants from Sangakai (aOR = 8.24, 95% CI 0.31–220.15) and Kanyerus (aOR = 8.32, 95% CI 0.40–172.04), and two times highly likely in participants from Longarkau (aOR = 2.02, 95% CI 0.04–110.05) and Pkotong (aOR = 2.02, 95% CI 0.04–110.5). The odds of infection with ZIKV in West Pokot was twice as high in males compared to females (aOR = 2.01, 95% CI 0.91–4.41).

Discussion

The present study reports on the serological evidence of human exposure to *Flaviviruses* in West Pokot and Turkana counties of northern Kenya. Overall, we found that 14.5% ($n = 127$, 95% CI 12.3–17.0%) of the samples were positive for at least one flavivirus (ZIKV, YFV, DENV-2, WNV). However, there were variations in the rates of human exposure for the individual viruses between the counties and across sites. Such variation in prevalence by site or even region is not uncommon in Kenya [27–29]. At the county level, seroprevalence ranged from 0.22% for DENV in West Pokot to 10.7% for YFV in Turkana. Much higher exposure of specific flavivirus has
Such variability in specific flavivirus as observed been observed, of up to 60% for DENV in coastal Kenya [27, 30]. Such variability in specific flavivirus as observed in our study and elsewhere in Kenya suggests exposure is likely conditioned by a myriad of ecological and human factors such as vector species and abundance, climate and weather patterns, environmental features, occupational activities, degree of mobility among others.

West Nile virus was detected in Turkana (42/413, 10.2%), but not in West Pokot. This difference could relate partly to ecological variation between the two areas. West Nile virus is associated with Culex mosquitoes, the virus having been previously isolated in some Culex species in Kenya [31–33]. It is possible the mosquito fauna especially the Culex spp. abundance and diversity varies between the areas. Grossi-Soyster [29] found high risk of both alphaviruses and flaviviruses primarily associated with households near the Lake area in Western Kenya. In this case, the presence of a lake (Lake Turkana) may encourage high diversity of bird species and breeding of Culex species, which are important determinants of the epidemiology of WNV [2]. This may possibly account for higher exposure rates in humans in Turkana than West Pokot. Proximity to Lake Turkana may also influence the economic activities of the people living in the area, such as fishing or grazing livestock. Older men spend more time away from home fishing, taking care of the livestock and looking after pasture in areas around the lake. Such outdoor activities could predispose them to more mosquito infectious bites. This could explain the obvious disparity in exposure rates among males compared to females, even though more samples were analyzed from the latter relative to the former. In fact, males were about three times more likely to be infected with WNV than females (aOR = 2.55, 95% CI 1.22–5.34). Additionally, adult males aged 50+ had more exposure, consistent with previous findings [30]. This alludes to higher risk due to advanced age; however, exposure in the 13–19 age group is indicative of ongoing transmission of this virus. Evidence of isolation of the virus from Culex spp. in this ecology [33] lends support for active virus transmission.

Table 3 Comparison of Flavivirus prevalence by site, demographic parameters and history of YF vaccination from Firth’s multiple logistic regression model

| Variable                 | West Pokot (N = 464) |                      | West Pokot (N = 464) |                      | Turkana (N = 413) |                      | Turkana (N = 413) |
|--------------------------|----------------------|----------------------|----------------------|----------------------|-------------------|----------------------|-------------------|
| Yellow fever (n = 6)     |                      | aOR (95% CI) Pvalue  |                      | aOR (95% CI) Pvalue  |                      | aOR (95% CI) Pvalue  |                      |
| Kokipei Reference        |                      |                      | Sangakai Reference   |                      |                   |                      |                   |
| 8.24 (0.31–20.15)        | 0.028                | 0.77 (0.23–260)      | 0.669                | 0.42 (0.10–1.79)     | 0.240              | 0.98 (0.21–4.69)     | 0.982              |
| Kanyerus Reference       |                      |                      | Shaba Reference      |                      |                   |                      |                   |
| 8.32 (0.40–172.04)       | 0.170                | 1.10 (0.41–2.93)     | 0.853                | 0.32 (0.10–1.04)     | 0.058              | 0.94 (0.28–3.17)     | 0.925              |
| Longarkau Reference      |                      |                      | Old gunner Reference |                      |                   |                      |                   |
| 2.02 (0.04–110.5)        | 0.731                | 0.24 (0.04–146)      | 0.122                | 0.39 (0.12–1.22)     | 0.106              | 0.88 (0.24–3.14)     | 0.838              |
| Pkotong Reference        |                      |                      |男               Reference |                      |                   |                      |                   |
| 2.02 (0.04–1043.4)       | 0.728                | 0.36 (0.08–167)      | 0.191                | 0.39 (0.15–0.99)     | 0.047              | 1.45 (0.49–43)       | 0.505              |
| Age group                |                      |                      |                      |                      |                   |                      |                   |
| 13–19 Reference          |                      |                      | 20–29 Reference      |                      |                   |                      |                   |
| 0.82 (0.03–24.26)        | 0.910                | 0.35 (0.07–1.81)     | 0.209                | 1.26 (0.41–3.84)     | 0.686              | 0.76 (0.22–2.66)     | 0.663              |
| 30–39 Reference          |                      |                      | 30–39 Reference      |                      |                   |                      |                   |
| 1.76 (0.08–3873)         | 0.721                | 0.42 (0.09–207)      | 0.288                | 1.59 (0.52–484)      | 0.414              | 1.43 (0.41–4.92)     | 0.574              |
| 40–49 Reference          |                      |                      | 40–49 Reference      |                      |                   |                      |                   |
| 1.06 (0.04–30.49)        | 0.975                | 0.45 (0.09–231)      | 0.337                | 1.03 (0.26–401)      | 0.970              | 1.09 (0.24–4.94)     | 0.912              |
| 50+ Reference            |                      |                      | 50+ Reference        |                      |                   |                      |                   |
| 0.39 (0.01–122.6)        | 0.595                | 0.34 (0.07–159)      | 0.169                | 0.72 (0.22–238)      | 0.589              | 2.10 (0.66–66)       | 0.206              |
| Herdsman                 |                      |                      |                      |                      |                   |                      |                   |
| No Reference             |                      |                      | No Reference         |                      |                   |                      |                   |
| 3.16 (0.2–48.99)         | 0.411                | 1.16 (0.36–372)      | 0.806                | 0.93 (0.27–3.28)     | 0.915              | 1.40 (0.52–3.74)     | 0.508              |
| Yellow fever vaccinated  |                      |                      |                      |                      |                   |                      |                   |
| No Reference             |                      |                      | No Reference         |                      |                   |                      |                   |
| 0.61 (0.09–3.91)         | 0.599                | 1.05 (0.42–260)      | 0.924                | 0.81 (0.13–5.13)     | 0.819              | 1.70 (0.34–8.57)     | 0.519              |
| Don’t know               |                      |                      |                      |                      |                   |                      |                   |
| 1.45 (0.22–7.97)         | 0.701                | 2.90 (1.11–760)      | 0.030                | 1.21 (0.61–241)      | 0.586              | 0.75 (0.37–153)      | 0.427              |
Neutralizing antibodies against YFV were detected in samples from both counties, although significantly higher in Turkana than West Pokot \((P < 0.0001)\). Site specific variation in exposure rates was also evident ranging from 7% in Kere Edome to about 20% in Eleela in Turkana County. It has been about three decades since the last documented outbreak of YF in Kenya in the neighboring Rift Valley [4, 5]. The exposure in the 13–19 age group, although higher in 30–39 age category, could indicate low-level ongoing transmission and persistent exposure in this region. The participants’ responses to their YF vaccination status made it difficult to determine the definite source of infection for YF reactive samples. Record of vaccination status was based on self-reporting which could not be verified, as no vaccination cards were provided during survey. However, the presence of YF neutralizing antibodies in these two counties may be attributable in part to the vaccinations that were rolled out in 2003 in response to the outbreak that was reported in the neighboring South Sudan [6]. Additionally, anecdotal information from the Kenyan Ministry of Health and Sanitation suggests that, some of the population received YF vaccination in Uganda in response to the 2011 YF outbreak [7], while they had crossed the borders to Uganda for pasture and trade. However, the level of immunity seems too low for a population that was vaccinated so recently to forestall an outbreak from a neighboring country. If vaccination was carried out to prevent an outbreak, then a seroprevalence of 10% is a far cry from the desired protective herd immunity level (80%) and should be enhanced. We also cannot rule out the circulation of YF in low levels in these regions, because of cross border travel by this population to outbreak areas in the neighboring countries in search of pasture and trade contributing to this high seroprevalence. Our findings somehow point to active circulation of YFV in low levels in these regions; similar exposure rates have been observed in other regions of Kenya [30].

Only one sample in West Pokot was reactive to DENV-2 and none from Turkana. This in part may suggest low human exposure to this serotype in this region. Previous studies have highlighted the prevalence of DENV-2 serotype in Kenya through serological studies [12, 28, 34]. Nonetheless, human exposure to the other serotypes (1, 3–4) has been reported [30]. While we employed PRNT which is the gold standard for determining serological specific among viruses, cross reactivity of human sera, however, occurs with all four DENV serotypes [35] and even with other flaviviruses. The limitation of our analysis to only a single serotype (DEN-2), suggests more studies are needed to determine the exact burden of DEN in this region and possibly establish the serotype distribution.

The results in the current study suggest circulation of Zika in both counties, yet there have never been reported or confirmed cases of ZIKV in Kenya. The prevalence of Zika was significantly higher in West Pokot than in Turkana County. Coincidentally, the highest seroprevalence was recorded in Kanyerus (Fig. 1), proximal to the Uganda where the virus was first detected in 1947 [13]. Exposure could be influenced by the degree of human mobility between this site and across border into Uganda. As nomadic pastoralists, long distance movement of livestock in search of pasture or water is common practice especially during drought. Few studies have reported data on human exposure to ZIKV in Kenya, the last dating > 40 years [36]. The high prevalence among the age group 13–19 years possibly indicates evidence of active circulation of this virus in this ecology, which may have gone unnoticed due to lack of detection facilities. This calls for focused arboviral surveillance to forestall severe consequences of the virus emergence and incriminate the important vectors to enhance preparedness in dealing with potential outbreaks.

Our sampling approach focused only on asymptomatic population and could not tell whether the exposure represented here did manifest clinically. It is well known that clinical presentations of arboviral diseases are often highly non-specific, commonly indistinguishable from each other and from other common tropical diseases like malaria [37]. The lack of diagnostic capability for arboviruses being routinely implemented in any health facility in the study area makes tracking of clinical cases very difficult, outside the confines of research studies. The need for continuous monitoring remains a priority given the unanticipated emergence or reemergence of arboviral diseases in recent years mainly in the form of outbreaks. Active surveillance including virus activity in vectors would help to shed light on the specific vectors involved and risk trajectory. Such studies could employ emerging technologies such as Next Generation Sequencing (NGS) to identify and characterize even unknown pathogens that could potentially be of human health impact.

This study has some limitations that should be considered. Our sampling approach targeted asymptomatic population in a cross-sectional study design. There was no clinical information related to these infections in the study population. Further studies should include clinical disease monitoring and should be extended to include young children and pregnant women, as in the case of ZIKV which has been found to be associated with congenital birth defects, including microcephaly in the developing fetus [38]. In PRNT analysis, we employed only DENV-2 serotype which affects definite conclusions that can be drawn regarding DEN exposure and other serotypes in the study areas. Also, while we used the Firth's
logistic regression model to reduce bias in estimates and to overcome the computational problems experienced with the conventional logistic regression model, the low frequencies of the viruses – as has been reported in the literature – does make it difficult to associate the prevalence with the risk factors.

**Conclusion**

The findings have demonstrated human exposure to infections with *Flaviviruses* in West Pokot and Turkana counties of Kenya. The presence of West Nile and Zika virus neutralizing antibodies in this population especially in the 13–19 age group shows that the viruses have recently been circulating undetected in human populations in this region. This suggests that there is a risk of WNV transmission in Turkana and ZIKV transmission in West Pokot County. The variable exposure risk observed between the areas could be related to differences in climate and geography between them. Therefore, it would be worthwhile for future studies to assess the local mosquito fauna composition and abundance trends, and investigate their vector competence to transmit ZIKV, in order to shed light on the high prevalence observed. Evidence of YF seropositivity may partly be due to previous vaccination, and if so, there is a potential risk of YF transmission if vaccination is not enhanced to improve herd immunity to protective level of 80%, considering proximity to an outbreak area across the border. One Health approach through active surveillance to integrate the myriad of factors involved in modulating human exposure risk is crucial to develop a decision support tool for accurate risk assessment. Overall, the findings provide needed evidence of human exposure, for action to towards disease prevention plans and the activation of preparedness strategies to counter potential threats posed by these viruses.

**Additional file**

**Additional file 1**: Table S1. Prevalence of Zika virus (West Pokot County) and Yellow Fever, West Nile (Turkana County) by demographic characteristics. (DOCX 19 kb)

---

**Abbreviations**

- aORs: Adjusted odds ratios
- CI: Confidence Interval
- DENV: Dengue virus
- EID: Emerging Infectious Diseases
- GIS: Geographic Information System
- GPS: Global Positioning System
- ML: Maximum Likelihood
- NGS: Next Generation Sequencing
- PRNT: Plaque Reduction Neutralization Test
- RPM: Revolutions per Minute
- WHO: World Health Organization
- WNV: West Nile virus
- YFV: Yellow fever virus
- ZIKV: Zika virus

**Acknowledgements**

We acknowledge the contribution of Joan Lichoti (icipe, Nairobi) for project management. We recognize the technical support of the Viral Hemorrhagic Fever Laboratory team members (KEMRI, Nairobi). We are grateful to Jackson Kimani, GIS support unit, icipe for producing the map of the study area. We wish to thank Benedict Orindi for statistical guidance. We are also grateful for the support from the local chiefs as well as community members of Kacheliba, West Pokot and Lokitoung, Turkana Counties.

**Funding**

EC was supported by a German Academic Exchange Service (DAAD) In-Region Postgraduate Scholarship and a L’Oreal-UNESCO for Women in Science Scholarship. We gratefully acknowledge the financial support for this research by the following organizations and agencies: National Institutes of Health (NIH), Grant No. 1R01AI099736-01A1 to RS; UK Aid from the UK Government; Swedish International Development Cooperation Agency (Sida); the Swiss Agency for Development and Cooperation (SDC); and the Kenyan Government. The views expressed herein do not necessarily reflect the official opinion of the donors.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article.

**Authors’ contributions**

EC conceived and drafted the manuscript. EC, SLK, JL, FE, participated in serology aspects of the laboratory analysis. EC, CT and ZI coordinated field activities and the logistics of sample collection from the sites to the laboratory. RS, DPT and MV contributed to overall study design, overall supervision of implementation, data analysis, and final manuscript preparation. RS mobilized resources for the study. All authors read and approved the final manuscript.

**Consent for publication**

Not applicable

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1International Centre of Insect Physiology and Ecology, P. O. Box 30772-00100, Nairobi, Kenya. 2Center for Viral Zoonoses, Department of Medical Virology, University of Pretoria, P. O. Box 323, Arcadia 0007, South Africa. 3Center for Virus Research, Kenya Medical Research Institute, P. O. Box 54628-00200, Nairobi, Kenya. 4Division of Disease Surveillance and Response, Ministry of Health, P. O. Box 20781-00202, Nairobi, Kenya. 5Jomo Kenyatta University of Agriculture and Technology, P.O. Box 606, Village Market, Nairobi, Kenya.

Received: 25 February 2019 Accepted: 6 May 2019
Published online: 17 May 2019

**References**

1. Huang YS, Higgs S, Horne KM, VanLandingham DL. Flavivirus-Mosquito Interactions. Viruses. 2014;6(11):4703–30.
2. Nyamwaiwa D, Wang’ondu V, Animjo I, Michuki G, Opgugo M, Ontri E, et al. Detection of West Nile virus in wild birds in Tana River and Garissa counties, Kenya. BMC Infect Dis. 2016;16:696.
3. Weetman D, Kamgang B, Badolo A, Moyes CL, Shearer FM, Coulibaly M, et al. Aedes mosquitoes and Aedes-borne arboviruses in Africa current and future threats. Int J Environ Res Public Health. 2018;15:220.
4. Sanders EJ, Marfin AA, Tukey PM, Kuria G, Ademba G, Agata NN, et al. First recorded outbreak of yellow fever in Kenya, 1992-1993. I. Epidemiologic investigations. Am. J. Trop. Med. Hyg. 1998;59(4):644–9.
5. Reiter P, Cordellier R, Ouma JO, Cropp CB, Savage HM, Sanders EJ, et al. First recorded outbreak of yellow fever in Kenya, 1992-1993. II. Entomologic investigations. Am. J. Trop. Med. Hyg. 1998;59(4):650–6.
6. Onyango CO, Olufa VO, Sang RK, Konongoi SL, Sow A, De Cock KM, et al. Yellow fever outbreak, Imatong, southern Sudan. Emerg Infect Dis. 2004; 10(6):1063–8.
7. World Health Organization. Yellow fever, Uganda.2011; (86):[37–44 pp].
8. World Health Organization. Yellow fever-Uganda. 2016. http://www.who.int/csr/don/02-may-2016-yellow-fever-uganda/en/. Accessed 6 Jan 2019.
9. Lílý A, Asamene N, Bekele A, Mengesha M, Wendabeku M, Tareke I, et al. Reemergence of yellow fever in Ethiopia after 50 years, 2013.
epidemiological and entomological investigations. BMC Infect Dis. 2017; 17(1):343.
10. Kraemer MU, Faria NR, Reiner RC Jr, Golding N, Nikolay B, Stasse S, et al. Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015-16: a modelling study. Lancet Infect Dis. 2017; 17(2):330-8.
11. Ellis EM, Neatherlin JC, Dekrey M, Ochieng M, Mohamed AH, Mogeni DO, et al. A household serosurvey to estimate the magnitude of a dengue outbreak in Mombasa, Kenya. 2013. PLoS Negl Trop Dis. 2015;9(4):e0003733.
12. Konongolo L, Ofua V, Nyunja A, Owaka S, Koka H, Makio A, et al. Detection of dengue virus serotypes 1, 2, and 3 in selected regions of Kenya: 2011-2014. Virol J. 2016;13:1.
13. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46:509–20.
14. Filipe AR, Martins CM, Rocha H. Laboratory infection with Zika virus after vaccination against yellow fever. Arch Gesamte Virundorsch. 1973;43:315–9.
15. Simpson DI. Zika virus infection in man. Trans R Soc Trop Med Hyg. 1964;48:355–8.
16. Kindhauser MK, Allen T, Frank V, et al. Zika: the origin and spread of a mosquito-borne virus. Bull World Health Organ. 2016;94(9):675–86.
17. Wikin N, Smith DR. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis. 2016;16:e119–26.
18. Serie C, Lindrec A, Poirier A, Andral L, Neri P. Studies on yellow fever in Ethiopia. I. Introduction-clinical symptoms of yellow fever. Bull World Health Organ. 1968;38(6):835–41.
19. Kenya National Bureau of Statistics. Census report. 2009. http://www.knbs.or.ke/index.php?option=com_phocadownload&view=category&id=109:population-and-housing-census-2009&Itemid=599. Accessed 6 Jan 2019.
20. Tigoi C, Lwande O, Orindi B, Irura Z, Ongus J, Sang R. Seroepidemiology of selected arboviruses in febrile patients visiting selected health facilities in the Lake/River Basin areas of Lake Baringo, Lake Naivasha, and Tana River, Kenya. Vector Borne and Zoonotic Diseases. 2015;15(2):124–32.
21. Odihambo C, Venter M, Swanepoel R, Sang R. Orthobunyavirus antibodies among humans in selected parts of the rift valley and northeastern Kenya. Vector Borne Zoonotic Dis. 2015;15(3):329–32.
22. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008;21:123–32.
23. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008.
24. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Statistical Sci. 2001;16:101–33.
25. Firth D. Bias reduction of maximum likelihood estimates. Biometrica. 1993; 80(1):27–38.
26. Heine G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409–19.
27. Ochieng C, Ahenda P, Vittor AY, Nyoka R, Gikunju S, Wachira C, et al. Seroprevalence of infections with dengue viruses in Kenya, 2007. PLoS One. 2007;10(7):e132645.
28. Vu DM, Banda T, Teng CY, Heinbaugh C, Muchit EM, Mungai PL, Mutuku FM, Brichard J, Gildengorin G, Borland EM, Powers AM, Kiron U, King CH, LaBeaud AD. Dengue and West Nile virus transmission in children and adults in coastal Kenya. Am J Trop Med Hyg. 2016;95(4):141–3.
29. Grosi-Soyrer EN, Cook EA, de Glanville WA, Thomas LF, Krysztofik AR, Lee J, Wamae CN, Karuki S, Fèvre EM, LaBeaud AD. Serological and spatial analysis of alphavirus and flavivirus prevalence and risk factors in a rural community in western Kenya. PLoS Negl Trop Dis. 2017;11(10):e0005998.
30. Sutherland LJ, Cash AA, Huang YJ, Sang RC, Malhotra I, Mooiramm AM, King DL, Weaver SC, King CH, LaBeaud AD. Serologic evidence of arboviral infections among humans in Kenya. Am J Trop Med Hyg. 2011;85(1):156–61.
31. Miller BR, Nasci RS, Godfrey MS, Savage HM, Lutzwa MJ, Lanciotti RS and Peters CJ. 2000:62;240–6. First field evidence for natural vertical transmission of West Nile virus in Culex univittatus complex mosquitoes from Rift Valley province, Kenya. Am J Trop Med Hyg. 2000;62:240–6.
32. LaBeaud AD, Sutherland LJ, Muiruri S, Muchir EM, Gray LR, Zimmerman PA, Hise AG, King CH. Arbovirus prevalence in mosquitoes, Kenya. Emerg Infect Dis. 2011;17(2):333–41.
33. Ochieng C, Lutomiah J, Makio A, Koka H, Chepkorir E, Yalwala S, et al. Mosquito-borne arbovirus surveillance at selected sites in diverse ecological zones of Kenya; 2007 – 2012. Virol J. 2013;10(1):140.